Litcius/Paper detail

Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases

Lucas Guillo, María T. Abreu, Remo Panaccione, William J. Sandborn, Valderílio Feijó Azevedo, Lianne S. Gensler, Bahar Moghaddam, Vineet Ahuja, Sabrina A Ali, Matthieu Allez, Ashwin N. Ananthakrishnan, Abhik Bhattacharya, Marla C. Dubinsky, Anne M. Griffiths, Ailsa Hart, Burton I. Korelitz, Paulo Gustavo Kotze, Ioannis E. Κoutroubakis, Péter L. Lakatos, James O. Lindsay, Fernando Magro, Gerassimos J. Mantzaris, Siew C. Ng, Colm O’Morain, Julián Panés, Tommaso Lorenzo Parigi, Zhihua Ran, Gerhard Rogler, David T. Rubin, David B. Sachar, Britta Siegmund, Flávio Steinwurz, Curt Tysk, Stephan R. Vavricka, Sofia G. Verstraete, Antoine P. Brézin, Anna Haemel, Axel Dignaß, Bruce E Sands, Silvio Danese, Laurent Peyrin‐Biroulet

2022˜The œLancet. Gastroenterology & hepatology36 citationsDOI

Topics & Concepts

MedicineInflammatory bowel diseaseClinical endpointReferralClinical trialIntensive care medicineDiseaseConsensus conferenceInflammatory Bowel DiseasesInternal medicinePhysical therapyFamily medicineInflammatory Bowel DiseaseAutoimmune and Inflammatory DisordersSpondyloarthritis Studies and Treatments
Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases | Litcius